Drew McCartney, Operating Committee Member of BelHealth, Joins Skila as Chief Executive Officer
Skila, a leading provider of fully managed Software-as-a-Service (SaaS) product launch management and key opinion leader (KOL) management solutions to pharmaceutical and medical device companies, is pleased to announce the appointment of Drew McCartney as CEO. Mr. McCartney has served in a variety of executive roles for companies in the medical devices, services and informatics industry and brings a sense of the client’s perspective that will be additive to the successes that Skila has achieved.
Morris Plains, NJ, August 25, 2011 --(PR.com)-- Skila, a leading provider of fully managed Software-as-a-Service (SaaS) product launch management and key opinion leader (KOL) management solutions to pharmaceutical and medical device companies, is pleased to announce the appointment of Drew McCartney as Chief Executive Officer.
Harold Blue, Managing Partner of BelHealth Investment Partners L.P. (“BelHealth”), and Chairman of the Board of Skila, said, “I am pleased and excited to have Drew lead our team at Skila and help drive our ambitious plans via organic growth and acquisitions to establish Skila as the leader in product lifecycle management and key opinion leader (KOL) management solutions throughout the life science industry."
Mr. McCartney has served in a variety of executive roles, including as CEO, for companies in the medical devices, services and informatics industry. Mr. McCartney started his career with American Hospital Supply and was VP of Global Marketing with Baxter Biotech. Mr. McCartney developed and executed the global strategic marketing direction for Baxter's $250 million blood systems unit, through which the company achieved significant sales growth, new product introductions and licensing relationships with partners worldwide.
More recently, Mr. McCartney served as the Executive-In-Residence at DW Healthcare Partners, a healthcare focused private equity fund. Prior to that, Drew was CEO of First Circle Medical and raised substantial capital from a combination of Boston Scientific Corporation, Tyco International and private equity and established commercial operations in Europe and China. Mr. McCartney also led a private equity-backed catheter stabilization company through a critical restructuring while developing and commercializing a number of technologies overseas and domestically.
Previously, Mr. McCartney was with the Battelle Memorial Institute and led their expansion into new healthcare markets in drug delivery and clinical informatics. Mr. McCartney holds a bachelor's degree in Government from the University of Virginia.
Simon Mason, the President and Chief Operating Officer of Skila, said, “Drew is an excellent choice as leader for Skila as the company enters a period of significant expansion. His strong management experience and in-depth understanding of our industry will help continue to drive growth at Skila. I am looking forward to working closely with Drew.”
Commenting on his appointment as CEO of Skila, Mr. McCartney said "I am truly excited about this opportunity. Skila has a unique business model and strategy, which focuses on helping its customers drive sales, maintain compliance and achieve their business goals. Having run an array of health care technology growth platforms, I’ll bring a sense of the client’s perspective that will be additive to the successes that Skila has achieved working with the world’s leading pharmaceutical companies. Coming from prior private equity sponsored assignments, I can readily discern where M&A opportunities are abundant to extend and scale Skila’s suite of services for its life sciences partners. I am looking forward to taking the company to the next level.”
###
Harold Blue, Managing Partner of BelHealth Investment Partners L.P. (“BelHealth”), and Chairman of the Board of Skila, said, “I am pleased and excited to have Drew lead our team at Skila and help drive our ambitious plans via organic growth and acquisitions to establish Skila as the leader in product lifecycle management and key opinion leader (KOL) management solutions throughout the life science industry."
Mr. McCartney has served in a variety of executive roles, including as CEO, for companies in the medical devices, services and informatics industry. Mr. McCartney started his career with American Hospital Supply and was VP of Global Marketing with Baxter Biotech. Mr. McCartney developed and executed the global strategic marketing direction for Baxter's $250 million blood systems unit, through which the company achieved significant sales growth, new product introductions and licensing relationships with partners worldwide.
More recently, Mr. McCartney served as the Executive-In-Residence at DW Healthcare Partners, a healthcare focused private equity fund. Prior to that, Drew was CEO of First Circle Medical and raised substantial capital from a combination of Boston Scientific Corporation, Tyco International and private equity and established commercial operations in Europe and China. Mr. McCartney also led a private equity-backed catheter stabilization company through a critical restructuring while developing and commercializing a number of technologies overseas and domestically.
Previously, Mr. McCartney was with the Battelle Memorial Institute and led their expansion into new healthcare markets in drug delivery and clinical informatics. Mr. McCartney holds a bachelor's degree in Government from the University of Virginia.
Simon Mason, the President and Chief Operating Officer of Skila, said, “Drew is an excellent choice as leader for Skila as the company enters a period of significant expansion. His strong management experience and in-depth understanding of our industry will help continue to drive growth at Skila. I am looking forward to working closely with Drew.”
Commenting on his appointment as CEO of Skila, Mr. McCartney said "I am truly excited about this opportunity. Skila has a unique business model and strategy, which focuses on helping its customers drive sales, maintain compliance and achieve their business goals. Having run an array of health care technology growth platforms, I’ll bring a sense of the client’s perspective that will be additive to the successes that Skila has achieved working with the world’s leading pharmaceutical companies. Coming from prior private equity sponsored assignments, I can readily discern where M&A opportunities are abundant to extend and scale Skila’s suite of services for its life sciences partners. I am looking forward to taking the company to the next level.”
###
Contact
Skila, a Sela2 Company
Elaine M. Nowak
(973) 889-1300
www.skila.com
Elaine M. Nowak
(973) 889-1300
www.skila.com
Contact
Categories